ATIR shows better clinical results in patients receiving mismatched bone marrow transplantation

Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.

ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor.  The two year follow up data from the phase I/II study show no Transplant Related Mortality (TRM) in a group of 10 high risk leukemia patients who received an efficacious dose of ATIR™.  The overall survival of this group after two years is 70%.  These results compare favorably to outcomes of bone marrow transplantations from a full matching donor.

In addition, the FDA has granted ATIR™ an Orphan Drug Designation as a cell based therapy for the reduction of Transplant Related Mortality caused by Graft versus Host Disease (GvHD) and/or infections following allogeneic bone marrow transplantation.

Transplant Related Mortality is predominantly caused by acute Graft versus Host Disease (GvHD) or infections.  Today, bone marrow transplants require a full match between patient and donor, and prophylactic use of immune suppressants post transplantation is essential to limit and manage risk of acute GvHD.  However, this approach leaves patients without an active immune system for a prolonged period post transplantation, resulting in increased mortality due to infections.

ATIR™ is a cell based product of mismatched donor immune cells from which the acute GvHD causing cells have been removed.  By eliminating the risk of severe acute GvHD, the prophylactic use of immune suppressants can be avoided post transplantation, quickly giving patients a functioning immune system and ultimately resulting in a reduced Transplant Related Mortality (TRM).  

"The FDA's decision to grant ATIR an Orphan Drug Designation underscores the significant potential of our program for bone marrow transplant patients and their families. We are excited and encouraged by the clinical success to date, and are focused on rapidly developing ATIR to better serve this patient community," said Manja Bouman, CEO of Kiadis Pharma.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify key players in abnormal bone differentiation